Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active dermal patch Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

NCT01430312
View directory record Official record
Conditions
Healthy
Interventions
azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water, Sodium lauryl sulfate
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 25, 2026, 5:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rapid Effects of a Biofield Patch on Antioxidant Status and Cellular Energy

NCT07314359
View directory record Official record
Conditions
Antioxidant Status
Interventions
Active dermal patch, Placebo dermal patch
Other
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

NCT01597050
View directory record Official record
Conditions
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Interventions
R932333, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

NCT01984775
View directory record Official record
Conditions
Psoriasis
Interventions
GSK2894512 cream, Vehicle cream, Positive control, Negative control
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation

NCT01430533
View directory record Official record
Conditions
Healthy
Interventions
azelaic acid pre foam formulation, Vehicle pre foam formulation, Water
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Not applicable Interventional Results available

Low-dose UVA1 Radiation in Cutaneous Lupus Patients

NCT01776190
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus
Interventions
UVA1 radiation treatment
Device
Lead sponsor
Ben Chong
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 25, 2026, 5:02 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Longterm Effects of a Biofield Patch on Anxiety, Sleep, and Energy

NCT07353021
View directory record Official record
Conditions
Anxiety, Sleep
Interventions
Active dermal patch, Placebo patch
Device
Lead sponsor
Natural Immune Systems Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Klamath Falls, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 25, 2026, 5:02 AM EDT
Completed No phase listed Observational

A Non-drug Study Profiling Cutaneous Lupus

NCT01923415
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
Interventions
No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 25, 2026, 5:02 AM EDT
Recruiting Phase 2 Interventional

MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer

NCT06998342
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Short course radiation, Active Surveillance
Radiation · Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

NCT02448381
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
SGX301 (synthetic hypericin), Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

NCT00394693
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
Adenovirus Interferon gamma
Genetic
Lead sponsor
Transgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Stanford, California • Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Results available

Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)

NCT01682811
View directory record Official record
Conditions
Neurofibromatoses
Interventions
Part 1 Levulan injection, Part 1 Levulan surface application, Part 1 Levulan surface application twice, Part 1 Levulan surface application twice with microneedling, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2, Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 25, 2026, 5:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 25, 2026, 5:02 AM EDT